ライフサイエンスコーパス: plasma volume

1 Two to six sessions (1.2 plasma volumes).

2 calculated by subtracting true from apparent plasma volume.

3 nd the ingestion of sodium may help maintain plasma volume.

4 tagged albumin to measure red blood cell and plasma volume.

5 s associated with a significant expansion of plasma volume.

6 ttributed solely to the estimated changes in plasma volume.

7 nd hypovolemia led to a similar reduction in plasma volume.

8 rats, a model of normal renin with a raised plasma volume.

9 Alb data provided an independent estimate of plasma volume.

10 ietary sodium, which promotes an increase in plasma volume.

11 ed extracellular vesicle RNA using only 2 ml plasma volume.

12 uantify the BBB leakage rate and local blood plasma volume.

13 on Rayleigh scattering of microwaves on the plasma volume.

14 ANP), which acts with the kidney to regulate plasma volume.

15 bility may be part of a strategy to maintain plasma volume.

16 n arterial pressure in the face of decreased plasma volume.

17 lung weights, weight gain, hemodilution, and plasma volume.

18 body clearance required for ANP to regulate plasma volume.

19 ndocrine actions of ANP in the regulation of plasma volume.

20 ctivity and aldosterone in the regulation of plasma volume.

21 aldosterone given their marked reduction in plasma volume.

22 may be an indicator of an expanded maternal plasma volume.

23 nosis, but is challenging to detect from low plasma volumes.

24 ver, time consuming and requires significant plasma volumes.

25 This method permits analysis with lower plasma volumes (100 microL) and greater sensitivity (to

26 A simple protocol was developed for small plasma volumes (100-200 muL) by using isohexane (H) to e

27 uartile range, -282 to 335 mL]; P=0.035) and plasma volume (-138 mL, interquartile range, -379 to 154

28 Bed rest led to a reduction in plasma volume (17%), baseline PCWP (18%), SV (12%), LVED

29 In the subset of patients with an optimized plasma volume (2 mL), sensitivity was 69.6% (48/69; 95%

30 Patients with POTS had a greater deficit in plasma volume (334+/-187 versus 10+/-250 mL, P<0.001), r

31 ubjects with obese HFpEF displayed increased plasma volume (3907 mL [3563-4333 mL] versus 2772 mL [25

32 ntional therapy, appear to have a contracted plasma volume, a concept that is in contrast to the wide

33 Early natriuresis with a reduction in plasma volume, a consequent rise in haematocrit, improve

34 0 min) more than 95% of the peak increase in plasma volume after volume expansion (4.5% bovine serum

35 % saline was available in addition to water, plasma volumes after 24 h HU were not different from rat

36 rtension in UNx mice was associated with low plasma volumes, an increased rate of fetal resorption, i

37 essin occurred earlier than the reduction of plasma volume and atrial natriuretic peptide after Heart

38 thelial sodium channel antagonist normalized plasma volume and blood pressure, but only partially cor

39 triuretic peptide (ANP) in the regulation of plasma volume and blood pressure.

40 ology, including haemoglobin mass, blood and plasma volume and blood viscosity, cardiac output, blood

41 We assessed hemoglobin mass, plasma volume and blood volume in lowlanders at sea leve

42 ptations, including progressive increases in plasma volume and cardiac output.

43 ure ASGP-R concentration, as well as hepatic plasma volume and flow.

44 Plasma volume and fluid regulatory hormones were measure

45 RBCV, plasma volume and Hb(mass) all increased (P < 0.05) afte

46 eutic agent because of its ability to expand plasma volume and improve oncotic pressure in various cl

47 We measured plasma volume and plasma levels of atrial natriuretic pe

48 olume can help identify the heterogeneity in plasma volume and red blood cell mass that are features

49 Similar increases of plasma volume and supranormal cardiac index were observe

50 tion because pregnancy produces increases in plasma volume and the hemoglobin concentration decreases

51 from healthy donor plasma samples in minimal plasma volumes and outperformed KRAS mutation frequency

52 H/+ mice have decreased plasma volumes and significantly heavy stiff hearts.

53 ar end-diastolic volume, 2) exhibit a higher plasma volume, and 3) limit kidney injury and free-water

54 r and malaise, 'capillary leak' with loss of plasma volume, and coagulation defects which can lead to

55 Body mass and composition, plasma volume, and fasting concentrations of metabolic c

56 I and mean adjusted PSA concentrations, mean plasma volume, and mean adjusted PSA mass (total circula

57 n brown adipose tissue, minimal increases in plasma volume, and no increases in extracellular fluid v

58 del of high-renin hypertension with a normal plasma volume, and one-kidney, one clip (1K-1C) rats, a

59 dings support significant differences in BV, plasma volume, and red blood cell mass profile distribut

60 he aim of the study was to differentiate BV, plasma volume, and red blood cell mass profiles by pheno

61 of degradation of marker in the myocardium, plasma volume, and relative rate of loss of marker from

62 ance of myometrial quiescence, regulation of plasma volume, and release of neuropeptides, such as oxy

63 in the kidney, but did increase body weight, plasma volume, and the fluid content of abdominal fat pa

64 protein, resulting in chronically increased plasma volume, arterial hypertension, and cardiac hypert

65 outcome variable and the input total RNA or plasma volume as an exposure variable, which is equivale

66 mitation, we developed a bisulfite-free, low-plasma-volume assay by coupling cell-free methylated DNA

67 alculated as PSA concentration multiplied by plasma volume), assessed by determining P values for tre

68 The resulting mean plasma volume, assessed gravimetrically, was 11.6 muL wi

69 Obtained data were adjusted for different plasma volume at the two occasions.

70 protein-bound solutes were greater than the plasma volume, averaging 15 +/- 7 L for PCS and 14 +/- 3

71 decreasing the incidence of TRALI from high plasma volume blood products.

72 strated a higher prevalence of normal BV and plasma volume (both P<0.001).

73 High altitude exposure reduced plasma volume by 11% (P < 0.01) and increased pulmonary

74 iuretic peptide (ANP) acts acutely to reduce plasma volume by at least 3 mechanisms: increased renal

75 Preferential expansion of the plasma volume by infusion of salt-poor hyperoncotic albu

76 d its relation to regulating the circulating plasma volume by John Peters and subsequently Otto Gauer

77 of the longitudinal PV from microliter-sized plasma volumes can serve as a proxy for the shear PV mea

78 tal muscle injury attenuated the increase in plasma volume, cardiac index, or the repayment of system

79 The absence of plasma volume change would suggest that the mechanism po

80 number of transfusions but who received high plasma volume components from female donors.

81 dy, we identified patients who received high plasma volume components from male-only donors and compa

82 f strategies to minimize transfusion of high plasma volume components, fresh frozen plasma and aphere

83 In critically ill recipients of high plasma volume components, gas exchange worsened signific

84 ed the contributions and interactions of (i) plasma volume constriction; (ii) sympathoexcitation; and

85 natriuresis and osmotic diuresis, leading to plasma volume contraction and reduced preload, and decre

86 etic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and

87 chronic mountain sickness had a substantial plasma volume contraction, which alongside a higher red

88 With exercise, plasma volume-corrected levels of triglycerides decrease

89 ide most likely results in extracellular and plasma volume depletion and reduced systemic oxygen tran

90 lidation of clinically applicable methods of plasma volume determination as well as enhanced methodol

91 ERPF calculated by the product of fERPF and plasma volume, determined from patient weight, was compa

92 Plasma volume did not change.

93 Plasma volume disturbances have been implicated in some

94 al bisulfite-based dPCR assays require large plasma volumes due to cfDNA degradation, limiting clinic

95 obesity in older adults results in increased plasma volume, eccentric LV hypertrophy, and systolic an

96 is of sample amounts as low as sub-0.2 nL of plasma volume equivalents.

97 ed blood parameters (hemoglobin, hematocrit, plasma volume), exercise parameters (peak oxygen consump

98 ar mass of any of the current macromolecular plasma volume expanders, we found that it filtered readi

99 hemoglobin is more likely to reflect greater plasma volume expansion (and thus better maternal and of

100 compared with SL values: high altitude (HA), Plasma Volume Expansion (HA-PVX), Sildenafil (HA-SIL) an

101 normocythaemia (control), anaemia, anaemia + plasma volume expansion (PVX), anaemia + PVX + hypoxia,

102 mized sheep when compared with the resultant plasma volume expansion after a 50 mL/min of 0.9% infusi

103 Fractional plasma volume expansion after rapid infusion of saline o

104 compared with lean subjects, have decreased plasma volume expansion along with impaired iron homeost

105 Current estimates of plasma volume expansion are outdated and do not necessar

106 in LV filling and ejection was abolished by plasma volume expansion but to a lesser extent by silden

107 r study is needed to characterize diminished plasma volume expansion during pregnancy and to understa

108 - (RGZ) induced increases in body weight and plasma volume expansion found in control mice expressing

109 The failure of maternal plasma volume expansion has been implicated in adverse o

110 severe acute hypoproteinemia does not reduce plasma volume expansion in response to 50 mL/min 0.9% sa

111 Plasma volume expansion is an important component of a s

112 ividual patients who also have a compromised plasma volume expansion or pathologic homeostasis.

113 No difference was found in plasma volume expansion produced by a bolus of 50 mL/min

114 The plasma volume expansion reached approximately 20% at the

115 e Mountain, California) with and without (i) plasma volume expansion to sea level values and (ii) adm

116 Expansion (HA-PVX), Sildenafil (HA-SIL) and Plasma Volume Expansion with Sildenafil (HA-PVX-SIL).

117 ogesterone exposure are also associated with plasma volume expansion, and a leftward shift in the osm

118 okines), which causes systemic inflammation, plasma volume expansion, and cardiac hypertrophy and fib

119 is also accompanied by sodium retention and plasma volume expansion, and pregnant rats are resistant

120 The most frequent effects were due to plasma volume expansion, including conjunctival redness

121 ognition of runner's anemia, which is due to plasma volume expansion, with hemolysis from the poundin

122 ng metabolic dysfunction, such as failure of plasma volume expansion.

123 these effects may be mediated by inadequate plasma volume expansion.

124 to the plasma protein albumin after an acute plasma volume expansion.

125 gnancy (eg, treatment for mild hypertension, plasma-volume expansion, and corticosteroid use) have a

126 <0.001) and higher frequency of large BV and plasma volume expansions above normal (both P<0.001), wh

127 g, closed loop: 4.2 +/- 2 mL/kg; p < 0.001), plasma volume, extravascular volume (bolus resuscitation

128 Plasma volume fell, and plasma atrial natriuretic peptid

129 defined as a conjugate dose of 125 microg/mL plasma volume followed at 48 h by a clearing agent in a

130 gh yield of purified HDL from a low starting plasma volume for functional analyses.

131 vascular permeability (K(PS)) and fractional plasma volume (fPV) for each contrast medium.

132 othelial permeability (K(PS)) and fractional plasma volume (fPV) for each tumor.

133 R (B = -1.78, 95% CI -3.30, -0.27) and blood plasma volume fraction (B = -0.594, 95% CI -0.987, -0.20

134 statistics of the tracer kinetic parameters plasma volume fraction and volume transfer constant (K(t

135 al, permeability surface area product, blood plasma volume fraction, vascular pulsatility, and CVR (i

136 (b) dissociate preferential expansion of the plasma volume from decreases in sodium reabsorption by t

137 Volume transfer constant and plasma volume from dynamic contrast-enhanced MRI as well

138 low hematocrit may result from an increased plasma volume (hemodilution) or from reduced red blood c

139 ctomy, higher BMI was associated with higher plasma volume; hemodilution may therefore be responsible

140 ion of short-dipole-like radiation behavior, plasma volume imaging via ICCD photography, and measurem

141 Further studies evaluating plasma volume in HF may help to improve our understandin

142 d-to-tissue albumin clearance and changes in plasma volume in isoflurane-anaesthetized mice (C57BL/6J

143 e pressure was correlated with body mass and plasma volume in obese HFpEF (r=0.22 and 0.27, both P<0.

144 Despite the lower plasma volume in patients with POTS, there was not a com

145 hormonal systems, few studies have evaluated plasma volume in this condition under treatment.

146 therapy reduced the tumor vessel density and plasma volume in tumors to a greater extent than did the

147 calculation of intravascular volumes (RBCV, plasma volume) in patients with HF according to the Inte

148 ges during pregnancy include an expansion of plasma volume, increased cardiac output, decreased perip

149 n systemic vascular resistance, increases in plasma volume induced by sodium retention can manifest a

150 patients with decompensated HF, in whom the plasma volume is contracted despite an increase in total

151 This rise in plasma volume is exacerbated by CKD-induced systemic and

152 Plasma volume is expanded and plasma osmolality is decre

153 condary causes of erythrocytosis, in PV, the plasma volume is frequently expanded, masking the erythr

154 onsible for the lack of adequate decrease of plasma volume; its reduction can be taken as a marker of

155 er obese or not, were younger and had higher plasma volume, lower prevalence of atrial fibrillation,

156 dy mass index (BMI) have greater circulating plasma volumes, lower PSA concentrations among obese men

157 red with low dietary sodium intake increases plasma volume, lowers standing plasma norepinephrine, an

158 echnique in parallel with [14C]-sucrose as a plasma volume marker.

159 Clinical assessment of plasma volume may be of particular value during treatmen

160 toward a paradigm where hemoglobin mass and plasma volume may represent phenotypes with adaptive sig

161 Lower plasma volumes [median (IQR) = 5 (0-15) mL/kg vs 11 (5-3

162 It is likely that significant changes in plasma volume occur during intensification of medical th

163 his acidotic change; however, no increase in plasma volume occurred.

164 matocrits (20-50%) with an average recovered plasma volume of 61.7 +/- 2.6 muL.

165 samples were collected before and after one plasma volume of therapeutic plasma exchange (TPE).

166 y (CH) has been attributed to an increase in plasma volume or a change in cardiac nutrient preference

167 BMI was significantly associated with higher plasma volume (P < .001 for trend) and lower PSA concent

168 Plasma volume (P = 0.52) and body weight (P = 0.89) did

169 d sodium removal and substantially decreased plasma volume (P=0.005).

170 P < .01), with fewer TPE sessions and lower plasma volumes (P < .01 both).

171 n by an effect unrelated to expansion of the plasma volume, perhaps due to an effect of parathyroid h

172 signalling, altered renal oxygen tension or plasma volume perturbations.

173 ment over both the Schlegel and renal uptake plasma volume product estimates (p < 0.05).

174 od samples and the Schlegel and renal uptake plasma volume product scintigraphic techniques.

175 Plasma volume (PV) and blood volume (BV) were measured i

176 vial and subsynovial tissues of the TMJ, and plasma volume (PV) and permeability surface area product

177 POTS patients, and secondarily its effect on plasma volume (PV) and plasma norepinephrine.

178 We sought to test the hypothesis that plasma volume (PV) expansion in heart transplant recipie

179 high altitude (HA) experience a reduction in plasma volume (PV) that increases haemoglobin concentrat

180 Total haemoglobin mass (Hbmass) and plasma volume (PV) were measured by CO-rebreathing.

181 Plasma volumes ranged from 0.05 to 0.5 ml, and viral loa

182 hanges in plasma aldosterone levels, whereas plasma volumes ranged from 50% to 150% normal accompanie

183 lobin concentration is the result of greater plasma volume, rather than an absence of increased hemog

184 of 6% hydroxyethyl starch (potato-derived) [Plasma Volume Redibag (PVR); Baxter Healthcare, Thetford

185 , including increased urine output, enhanced plasma volume, reduced weight loss, and substantially im

186 We conclude that releasing plasma volume reduces adverse effects of TZD-induced vol

187 iates the early plasma volume reduction; (c) plasma volume reduction as well as ANP release depend on

188 and a PAF-ANP interaction mediates the early plasma volume reduction; (c) plasma volume reduction as

189 ar beds (such as gastro-intestinal tract) to plasma volume regulation.

190 In healthy persons, plasma volume remains relatively constant as a result of

191 nificantly shortened (p = .03), although the plasma volume required to achieve a durable remission wa

192 ing statistics and the overall laser-induced plasma volume suggests that the primary mechanism of par

193 Plasma volume, systemic hemodynamics, and oxygen transpo

194 ingle-copy assay [iSCA]), and increasing the plasma volume tested (Mega-iSCA).

195 Sherpa demonstrated a larger plasma volume than Andeans, resulting in a comparable to

196 Plasma volume, the intravascular portion of the extracel

197 rowth restriction), but so is failure of the plasma volume to expand.

198 cardiomyopathy, hypertension, and increased plasma volumes, together with increased ventricular supe

199 vestigate the correlation between fractional plasma volume (V(p)), a parameter derived from DCE perfu

200 Kb, hepatic plasma volume, Vh, extrahepatic plasma volume, Ve and hepatic plasma flow, F.

201 ed forward-binding rate constant Kb, hepatic plasma volume, Vh, extrahepatic plasma volume, Ve and he

202 ity-surface area product (PS) and fractional plasma volume ( vp ), and 4D flow MRI to assess cerebral

203 plaques were used to estimate the fractional plasma volume (vp) and transfer constant (Ktrans) of con

204 S) product after correction for the residual plasma volume (Vp) occupied by leptin in the vessel bed

205 extracellular space volume (Ve), fractional plasma volume (Vp)] were calculated, and their relations

206 Baseline plasma volume was 123 +/- 20% of normal; it was 122 +/-

207 nfusion, the estimated (89)Zr-trastuzumab in plasma volume was a median 102% (range, 78%-113%) of the

208 Blood plasma volume was highly variable and the only parameter

209 Plasma volume was markedly expanded following albumin in

210 Plasma volume was measured both pre- and postoperatively

211 Plasma volume was normalised to SL values, and hypoxic p

212 e plasmapheresis procedures during which one plasma volume was removed and replaced with fresh frozen

213 enhanced perfusion MRI parameter, fractional plasma volume, was able to differentiate between nonneop

214 thelial transfer coefficient, and fractional plasma volume were calculated for each tumor and each CM

215 anges, capillary filtration coefficient, and plasma volume were measured before and during the colloi

216 Plasma volumes were reduced during HU compared to rats i

217 We also measured plasma volume (with Evans blue dye) and maximal orthosta

218 online analysis compatibility, and a higher plasma volume yield.